16 July 2021
Telmisartan, medication sold under the brand name Micardis is consumed alone or in combination with other medications for decreasing the chances of heart attack or stroke among people above 55 years of age. The medication is consumed to control high blood pressure but cannot treat it. Telmisartan is an angiotensin II receptor blocker. As the medication lowers the blood pressure and blood and oxygen flow towards the heart more easily, therefore relaxes the blood vessels. Increasing number of patients of high blood pressure, and rising cases of chronic diseases is anticipated to grow Telmisartan market during the forecast period 2021-2031.
Get Exclusive PDF Sample Copy Of This Report: https://www.tmrresearch.com/sample/sample?flag=B&rep_id=7392
Increasing Incidences of Chronic Kidney Disease Globally
Loss in kidney functioning is one of the prime causes of death globally. With the primary reasons such as high blood pressure, diabetes, obesity, smoking, etc., need for telmisartan for moderately treating the kidney disease may grow further. According to International Society of Nephrology, there are almost 850 million people globally suffering from some kind of kidney disease. The prevalence of chronic kidney disease is 10.4% among men and 11.8% among women. In a recent study, researchers have found high dose of Telmisartan may be effective in patients suffering from chronic kidney disease, especially those who are suffering from overt proteinuria. Therefore, new researches and advances are helping the Telmisartan market to grow.
Increasing Cardiovascular Diseases
According to World Heart Federation, there are over 17 million deaths due to cardiovascular diseases globally. Out of which 9.4 million are due to raised blood pressure. Raised blood pressure contributes to the cause of almost 45% of all heart related deaths and 51% of all stroke related deaths. Researchers report that lowered blood pressure help in reducing heart attacks or cardiovascular events by 35-40%. Prevalent cases of cardiovascular diseases have nearly doubled in 20 years and therefore, the need for medication is more than ever. Number of deaths among cardiovascular patients globally was almost 18.6 million in 2019. Furthermore, with the increasing geriatric population in many parts of the world, the chances of people suffering with diseases are higher and thus, Telmisartan may have a lucrative demand.
Anti-Diabetic Effect of Telmisartan may be a Lucrative Opportunity for the Market
Telmisartan can be an alternative option with dual benefit for diabetes mellitus and hypertension. As per a research article published on ncbi.nlm.nih.gov, Telmisartan is reported to have a partial PPARy agonistic effect which modify the genes needed for insulin sensitization. Telmisartan can regulate glucose and lipid metabolism, therefore improves insulin resistance. Telmisartan promotes glucose uptake and act as insulin sensitizing agent in adipocytes. Therefore, usage of Telmisartan for anti-diabetic effect and hyper tension helps in lowering the amount of pills a person consumes thus, reducing the side effects which can occur due to consuming different medicines.
Get Special Discount on this Report : https://www.tmrresearch.com/sample/sample?flag=D&rep_id=7392
Severe Side Effects of the Medicine can inhibit the Growth
There can be many mild and severe side effects of the medicine. Back pain, sinus pain, congestion, diarrhoea, etc. can be the normal side-effects for which people mostly don’t stop taking the medicine. Some side effects such as swelling of the face, difficulty breathing, pain and cramping in the lower leg during walking, blistering of the skin or rash may get severe. The fear of side effects can act as a restrain to the market growth.
The key players in the sector include Mylan N.V., Jubilant Cadista, Sandoz International GmbH, Zydus Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., Aurobindo Pharma, Solco Healthcare, Exelan Pharmaceuticals, Inc., Medtronic Plc, KindWell Medical Equipment Co. Ltd., Neurovision Medical Products, Intersurgical GmbH, Sun Pharmaceutical Industries, Teva Pharmaceutical Industries ltd., etc.
Pfizer, Inc. in November 2020 announced their spinoff with Upjohn Business and combine it with Mylan N.V. to form Viatris, Inc. The company aims to strengthen the share-holders value and aims to provide better treatment and life changing medicines to the world. The combine company was named Viatris. Pfizer stockholders received approx. 0.124079 shares of Viatris common stock for every one share of Pfizer common stock held.
Sandoz International announced the joint plans with Austrian government to strengthen the long term future of integrated antibiotics manufacturing in Europe. The announcement was made in July 2020 and Sandoz plans to invest more than EUR 150 million over the next five years to strengthen their manufacturing operations at Kundl and for innovations for both pharmaceutical ingredients and finished dosage forms. The government funding aims to support new technology to produce API for penicillin products at Kundl.
Lupin in 2019 won the India Packaging Award regarding its patient awareness initiative ‘Lupin Sahayak’ and its special packaging for Telista which is a Lupin’s brand of Telmisartan and combinations. Sahayak is a new initiative by Lupin’s Synox team focussing on hypertension and diabetes.
The Telmisartan market is anticipated to have a significant market growth due to increasing geriatric populations and growing incidences of blood pressure, heart diseases, chronic kidney diseases, diabetes, etc. Also, patients with high blood pressure have increased risk of death due to covid-19 according to the European Heart Journal.
North America is projected to be the dominating market for Telmisartan market. Heart disease is one of the leading causes of death in US. According to Centre for Disease Control and Prevention, every 36 seconds, a person dies from cardiovascular disease in US and around 6,55,000 die from heart diseases every year. High blood pressure, high blood cholesterol, smoking are high risk factors for heart disease. About 47% of Americans suffer from any one of these key factors. Increasing unhealthy lifestyle is also the key reason for people to get high blood pressure problems. Thus, causing the telmisartan medicine to having a significant growth.
High blood pressure is responsible for half of all strokes and heart attacks. In UK, high blood pressure is the third biggest factor for all diseases after smoking and poor diet. Around one in three adults in UK suffer from high blood pressure. In England 31% of men and 26% of women have high blood pressure problems. Furthermore, cardiovascular disease is one of the leading causes of death in Europe Union causing almost 1.8 million deaths in Europe annually. Cardiovascular is estimated to cost EU around triple digit billions every year. And with covid-19, the numbers are expected to go higher therefore, being the second largest market during the forecast period.
Asia Pacific is expected to have a significant growth owing to increasing number of hypertension patients. Rising investment in healthcare infrastructure, growing research and development sectors in emerging economies is anticipated to grow the medical market in the region. Surge in funding by government and non-government organisations for initiating awareness regarding Telmisartan market. Increasing geriatric population in Japan and India are suffering from various cardiovascular diseases, therefore, deamiding the adoption of Temisartan medicine.
Request TOC of the Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=7392
Based on Indication
Cardiovascular Risk Reduction
Based on Distribution Channel
Based on Strength Type
Based on Composition
Based on Region
Middle East and Africa
Key Questions Answered
Who are the leading players in Telmisartan market?Mylan N.V., Jubilant Cadista, Sandoz International GmbH, Zydus Pharmaceuticals, Inc., Torrent Pharmaceuticals Ltd., Aurobindo Pharma, Solco Healthcare, Exelan Pharmaceuticals, Inc, etc.
Which region is anticipated to hold largest share in Telmisartan medicine?North America.
What are the classifications of Telmisartan based on Indication?Hypertension and cardiovascular risk reduction.
What are the key marketing trends?Growing patients suffering from chronic heart diseases, kidney effects, high blood pressure and diabetes.
What are the restraints in the market growth?Side effects, drug shortages, impact of covid-19, etc.
About TMR Research:
TMR Research is a premier provider of customized market research and consulting services to business entities keen on succeeding in today’s supercharged economic climate. Armed with an experienced, dedicated, and dynamic team of analysts, we are redefining the way our clients’ conduct business by providing them with authoritative and trusted research studies in tune with the latest methodologies and market trends.
3739 Balboa St # 1097,
San Francisco, CA 94121